You can help expand this article with text translated from the corresponding article in Spanish. (July 2021) Click [show] for important translation instructions.
|
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Other names | ABDALA |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
|
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
Abdala, technical name CIGB-66, is a COVID-19 vaccine developed by the Center for Genetic Engineering and Biotechnology in Cuba.[1] This candidate, named after a patriotic drama by Cuban independence hero José Martí, is a protein subunit vaccine containing COVID-derived proteins that trigger an immune response.[2] The full results of the clinical trial have not yet been published. This candidate followed a previous one called CIGB-669 (MAMBISA).[3]
The vaccine is one of two Cuba-developed COVID-19 vaccines which has passed Phase III trials,[4][5][6] and has received emergency authorisation.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search